Learn how Pfizer’s focus on immunotherapy aims to help people with multiple myeloma
Pfizer is studying a potential treatment for multiple myeloma that uses a person’s immune system to fight off cancer cells.
We are conducting a series of clinical trials, called the MagnetisMM studies, to evaluate the safety and effectiveness of a study medicine called elranatamab (el-ruh-NAH-tuh-mab).
Elranatamab is given as a subcutaneous injection (a needle inserted under the skin in order to deliver the study medicine). It is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells. Connecting these cells activates the immune cells to kill the myeloma cells.
The MagnetisMM studies will have their own unique requirements for who may participate (eligibility criteria). The requirements may include your stage of multiple myeloma as well as any previous treatments you may have received.
If you or a loved one are considering participating in these studies, find more information in the clinical trials list below.